Cargando…

The prognostic value of tumor-associated macrophages in glioma patients

Glioma is a complex tumor composed of both neoplastic and non-neoplastic cells, including tumor-infiltrating leukocytes (TILs), and each cell type contributes to tumor formation and malignant progression. Among TILs, tumor-associated macrophages (TAMs) are of great importance and play a key role in...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Yang, Zheng, Dingke, Hu, Dong, Ma, Baoxin, Cai, Chunsheng, Chen, Wei, Zeng, Jiahao, Luo, Junran, Xiao, Dan, Zhao, Yao, Wu, Zhiyan, Jing, Guojie, Xie, Yituan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519474/
https://www.ncbi.nlm.nih.gov/pubmed/37747032
http://dx.doi.org/10.1097/MD.0000000000035298
_version_ 1785109705988767744
author Shen, Yang
Zheng, Dingke
Hu, Dong
Ma, Baoxin
Cai, Chunsheng
Chen, Wei
Zeng, Jiahao
Luo, Junran
Xiao, Dan
Zhao, Yao
Wu, Zhiyan
Jing, Guojie
Xie, Yituan
author_facet Shen, Yang
Zheng, Dingke
Hu, Dong
Ma, Baoxin
Cai, Chunsheng
Chen, Wei
Zeng, Jiahao
Luo, Junran
Xiao, Dan
Zhao, Yao
Wu, Zhiyan
Jing, Guojie
Xie, Yituan
author_sort Shen, Yang
collection PubMed
description Glioma is a complex tumor composed of both neoplastic and non-neoplastic cells, including tumor-infiltrating leukocytes (TILs), and each cell type contributes to tumor formation and malignant progression. Among TILs, tumor-associated macrophages (TAMs) are of great importance and play a key role in the immune response to cancer. In this study, 22 types of adaptive and innate TILs were evaluated in gliomas. TAMs, which account for 38.7% of all these cells, are the most abundant immune infiltrates in the tumor microenvironment. In addition, we observed different immune cell patterns in low-grade glioma and glioblastoma. Our research indicated that there was a connection between TILs, and 13 of 22 TILs were significantly associated with patient outcomes. Finally, the prognosis and diagnostic value of TAMs were revealed using Kaplan–Meier analysis. We identified the optimal cutoff point of TAMs at an infiltrating level of 0.47 to predict patient prognosis, with a median overall survival of 448 days in patients with higher TAM infiltration levels and 2660 days in patients with lower TAM infiltration levels. These findings provide a new idea for glioma to regulate tumor-specific immunity, clarify the potential effects of TAMs on disease pathology, and provide a theoretical basis for immune intervention treatment of gliomas.
format Online
Article
Text
id pubmed-10519474
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-105194742023-09-26 The prognostic value of tumor-associated macrophages in glioma patients Shen, Yang Zheng, Dingke Hu, Dong Ma, Baoxin Cai, Chunsheng Chen, Wei Zeng, Jiahao Luo, Junran Xiao, Dan Zhao, Yao Wu, Zhiyan Jing, Guojie Xie, Yituan Medicine (Baltimore) 4100 Glioma is a complex tumor composed of both neoplastic and non-neoplastic cells, including tumor-infiltrating leukocytes (TILs), and each cell type contributes to tumor formation and malignant progression. Among TILs, tumor-associated macrophages (TAMs) are of great importance and play a key role in the immune response to cancer. In this study, 22 types of adaptive and innate TILs were evaluated in gliomas. TAMs, which account for 38.7% of all these cells, are the most abundant immune infiltrates in the tumor microenvironment. In addition, we observed different immune cell patterns in low-grade glioma and glioblastoma. Our research indicated that there was a connection between TILs, and 13 of 22 TILs were significantly associated with patient outcomes. Finally, the prognosis and diagnostic value of TAMs were revealed using Kaplan–Meier analysis. We identified the optimal cutoff point of TAMs at an infiltrating level of 0.47 to predict patient prognosis, with a median overall survival of 448 days in patients with higher TAM infiltration levels and 2660 days in patients with lower TAM infiltration levels. These findings provide a new idea for glioma to regulate tumor-specific immunity, clarify the potential effects of TAMs on disease pathology, and provide a theoretical basis for immune intervention treatment of gliomas. Lippincott Williams & Wilkins 2023-09-22 /pmc/articles/PMC10519474/ /pubmed/37747032 http://dx.doi.org/10.1097/MD.0000000000035298 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 4100
Shen, Yang
Zheng, Dingke
Hu, Dong
Ma, Baoxin
Cai, Chunsheng
Chen, Wei
Zeng, Jiahao
Luo, Junran
Xiao, Dan
Zhao, Yao
Wu, Zhiyan
Jing, Guojie
Xie, Yituan
The prognostic value of tumor-associated macrophages in glioma patients
title The prognostic value of tumor-associated macrophages in glioma patients
title_full The prognostic value of tumor-associated macrophages in glioma patients
title_fullStr The prognostic value of tumor-associated macrophages in glioma patients
title_full_unstemmed The prognostic value of tumor-associated macrophages in glioma patients
title_short The prognostic value of tumor-associated macrophages in glioma patients
title_sort prognostic value of tumor-associated macrophages in glioma patients
topic 4100
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519474/
https://www.ncbi.nlm.nih.gov/pubmed/37747032
http://dx.doi.org/10.1097/MD.0000000000035298
work_keys_str_mv AT shenyang theprognosticvalueoftumorassociatedmacrophagesingliomapatients
AT zhengdingke theprognosticvalueoftumorassociatedmacrophagesingliomapatients
AT hudong theprognosticvalueoftumorassociatedmacrophagesingliomapatients
AT mabaoxin theprognosticvalueoftumorassociatedmacrophagesingliomapatients
AT caichunsheng theprognosticvalueoftumorassociatedmacrophagesingliomapatients
AT chenwei theprognosticvalueoftumorassociatedmacrophagesingliomapatients
AT zengjiahao theprognosticvalueoftumorassociatedmacrophagesingliomapatients
AT luojunran theprognosticvalueoftumorassociatedmacrophagesingliomapatients
AT xiaodan theprognosticvalueoftumorassociatedmacrophagesingliomapatients
AT zhaoyao theprognosticvalueoftumorassociatedmacrophagesingliomapatients
AT wuzhiyan theprognosticvalueoftumorassociatedmacrophagesingliomapatients
AT jingguojie theprognosticvalueoftumorassociatedmacrophagesingliomapatients
AT xieyituan theprognosticvalueoftumorassociatedmacrophagesingliomapatients
AT shenyang prognosticvalueoftumorassociatedmacrophagesingliomapatients
AT zhengdingke prognosticvalueoftumorassociatedmacrophagesingliomapatients
AT hudong prognosticvalueoftumorassociatedmacrophagesingliomapatients
AT mabaoxin prognosticvalueoftumorassociatedmacrophagesingliomapatients
AT caichunsheng prognosticvalueoftumorassociatedmacrophagesingliomapatients
AT chenwei prognosticvalueoftumorassociatedmacrophagesingliomapatients
AT zengjiahao prognosticvalueoftumorassociatedmacrophagesingliomapatients
AT luojunran prognosticvalueoftumorassociatedmacrophagesingliomapatients
AT xiaodan prognosticvalueoftumorassociatedmacrophagesingliomapatients
AT zhaoyao prognosticvalueoftumorassociatedmacrophagesingliomapatients
AT wuzhiyan prognosticvalueoftumorassociatedmacrophagesingliomapatients
AT jingguojie prognosticvalueoftumorassociatedmacrophagesingliomapatients
AT xieyituan prognosticvalueoftumorassociatedmacrophagesingliomapatients